Teva confirms generic Victoza patent challenge

2 February 2017

Teva Pharmaceutical Industries (NYSE:TEVA) says that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration seeking approval to market the generic version of Victoza (liraglutide) injection, in the USA.

Danish diabetes care giant Novo Nordisk’s (NOV: N) Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Based on available information, Teva believes it is a "first applicant" to file an ANDA for the generic version of Victoza, and should its ANDA be approved, the Israeli generics giant may be entitled to 180 days of generic market exclusivity.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK